The expiration of semaglutide's patent in 2026 is expected to ignite competition among major global markets including China, India, the USA, Canada, and Brazil, particularly in the lucrative obesity treatment sector.
The expiration of the semaglutide patent in 2026 is poised to escalate competition among major players in the global pharmaceutical market, especially in the sector of weight loss medications based on incretins. As a class of drugs that regulate insulin release and appetite, GLP-1 agonists like semaglutide and dual agonists like tirzepatide have become key components in treating obesity, generating a dynamic and rapidly growing market. Forecasts for 2023 indicated a substantial increase in global sales, reflecting an unexpected surge in demand that has caught even experienced analysts off guard.
As the pharmaceutical industry braces for a rapid expansion period, the impending expiration of patents across various therapeutic areas—termed
